Skip to search formSkip to main contentSkip to account menu
  • Publications
  • Influence
EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndrome
TLDR
The ESSDAI is a clinical index designed to measure disease activity in patients with primary Sjögren's syndrome and should facilitate clinical research and be helpful as an outcome measure in clinical trials.
View on BMJ
Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force
TLDR
The 4 overarching principles and 10 recommendations are based on stronger evidence than before and are supposed to inform patients, rheumatologists and other stakeholders about strategies to reach optimal outcomes of RA.
View on BMJ
EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren's syndrome
TLDR
The EULAR SS Patient Reported Index is a very simple index designed to measure patients' symptoms in primary SS and has good construct validity and is well correlated with SSI and PROFAD.
View on BMJ
Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial
TLDR
Considering the limitations of an open-label study, adalimumab alone or in combination with standard DMARDs appeared to be well tolerated and effective in 6610 difficult-to-treat patients with active RA treated in clinical practice.
View on BMJ
EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide
TLDR
A user guide for the ESSDAI is provided, which provides definitions and precisions on the rating of each domain, and includes some minor improvement of the score to integrate advance in knowledge of disease manifestations.
View on BMJ
Pathogenetic mechanisms in the initiation and perpetuation of Sjögren's syndrome
TLDR
Patients with systemic extraepithelial manifestations display low serum levels of the complement component C4 and mixed type II cryoglobulins, and show an increased risk of developing non-Hodgkin lymphoma, thereby reflecting an overall worse prognosis with higher mortality rates than those without extraepIThelial manifestations.
View on Nature
Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjögren's syndrome.
TLDR
The determination of MMC can be used as a laboratory predictive factor for lymphoma development in primary SS and CRIs 17109 and G-6 may also be used to predict lymph cancer development, especially when the monoclonal component is absent.
View on PubMed
Single-Cell Analysis of Human Mononuclear Phagocytes Reveals Subset-Defining Markers and Identifies Circulating Inflammatory Dendritic Cells.
View on PubMed
Sjögren syndrome
TLDR
Knowledge of SjS has progressed substantially, but this disease is still characterized by sicca symptoms, the systemic involvement of disease, lymphocytic infiltration to exocrine glands, the presence of anti-Ro/SSA and anti-La/SSB autoantibodies and the increased risk of lymphoma in patients with SJS.
View on Nature
Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis.
TLDR
Anti-P antibody testing has limited diagnostic value for NPSLE, and it is not helpful in differentiating among various disease phenotypes.
View on PubMed
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License